Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Crispr Therapeutics Ag
(NQ:
CRSP
)
45.39
-0.35 (-0.77%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 29, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
845,715
Open
46.54
Bid (Size)
45.25 (3)
Ask (Size)
46.55 (3)
Prev. Close
45.74
Today's Range
45.22 - 46.97
52wk Range
38.94 - 68.06
Shares Outstanding
78,935,098
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Editas Medicine Is Beyond Skepticism, Analyst Has Confidence In Sickle Cell Therapy, Upgrades Stock
September 29, 2023
Stifel has upgraded Editas Medicine Inc (NASDAQ: EDIT), saying the company's sickle cell disease candidate, EDIT-301's progress, has received minimal credit from investors.
Via
Benzinga
Why Editas Medicine Stock Is Soaring Today
September 29, 2023
Investors are cheering a big analyst upgrade for the gene-editing stock.
Via
The Motley Fool
Performance
YTD
+10.71%
+10.71%
1 Month
-10.15%
-10.15%
3 Month
-19.15%
-19.15%
6 Month
+0.35%
+0.35%
1 Year
-29.62%
-29.62%
More News
Read More
If I Could Only Buy 3 Stocks in 2023, I'd Pick These
September 29, 2023
Via
The Motley Fool
Crispr Therapeutics, And CRISPR Gene-Editing, Face Their Make-Or-Break Moment
September 28, 2023
Via
Investor's Business Daily
Exposures
Product Safety
2 Bargain Growth Stocks to Buy Hand Over Fist
September 28, 2023
Via
The Motley Fool
Don’t Miss the Boom: 3 Pharma Stocks Set to Explode Higher
September 27, 2023
Via
InvestorPlace
2 No-Brainer Biotech Stocks to Buy Right Now
September 12, 2023
Via
The Motley Fool
From Dust to Diamonds: 7 Undervalued Stocks With Sparkling Prospects
September 27, 2023
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023
September 27, 2023
Via
Benzinga
Are Gene Therapy Stocks The Market's Next Big Winners?
September 25, 2023
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
2 Cathie Wood Stocks to Buy Hand Over Fist Right Now
September 24, 2023
Via
The Motley Fool
$10,000 Invested in These Growth Stocks Could Make You a Fortune Over the Next 10 Years
September 21, 2023
Via
The Motley Fool
Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio
September 20, 2023
Via
The Motley Fool
Flee to Healthcare Stocks if Recession Rears its Head?
September 20, 2023
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Where Will CRISPR Therapeutics Be in 5 Years?
September 19, 2023
Via
The Motley Fool
1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know
September 19, 2023
Via
The Motley Fool
2 Top Trends to Invest $500 In Right Now
September 18, 2023
Via
The Motley Fool
Looking for Growth? These Companies' Revenue May Skyrocket
September 17, 2023
Via
The Motley Fool
If You Invested $30,000 in CRISPR Therapeutics in 2016, This Is How Much You Would Have Today
September 16, 2023
Via
The Motley Fool
Better Growth Stock: Recursion Pharmaceuticals vs. CRISPR Therapeutics
September 15, 2023
Via
The Motley Fool
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
September 15, 2023
Via
Investor's Business Daily
Exposures
Product Safety
3 Top Healthcare Stocks Defying the Bear Market
September 15, 2023
Via
The Motley Fool
Better Bull Market Buy: CRISPR vs. Medtronic Stock
September 14, 2023
Via
The Motley Fool
3 Biotech Blockbusters to Turn $5,000 Into $50,000
September 12, 2023
Via
InvestorPlace
More Likely to 5x First: Bluebird Bio vs. CRISPR Therapeutics
September 12, 2023
Via
The Motley Fool
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.